



## Company Overview

Humanigen, Inc. is a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Derived from the company's Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets granulocyte-macrophage colony-stimulating factor (GM-CSF), is in development as a potential medicine to make chimeric antigen receptor T-cell (CAR-T) therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Ephrin type-A receptor 3 (EphA3), is under study as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers.

## Humanigen, Inc.

1000 Marina Boulevard  
Suite 250  
Brisbane, CA 94005

### Humanigen Completes Enrollment of Phase 1 Clinical Trial of Lenzilumab for Treatment of Chronic Myelomonocytic Leukemia

Mar 15 2018, 7:00 AM EDT

### Humanigen Appoints Robert Savage to Board of Directors

Mar 12 2018, 7:00 AM EDT

### Humanigen CEO to Present at Inaugural LD Micro Virtual Conference

Mar 1 2018, 4:15 PM EST

## Stock Overview

Symbol	HGEN
Exchange	OTCQB
Shares OS	14,986,712
Market Cap	\$10.04M
Last Price	\$0.67
52-Week Range	\$0.125 - \$2.98

## Investor Relations

MZ Group  
Mike Cole  
T: 949-259-4988  
[mike.cole@mzgroup.us](mailto:mike.cole@mzgroup.us)

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.